




 American Scientific Research Journal for Engineering, Technology,  and Sciences  (ASRJETS) 
ISSN (Print) 2313-4410, ISSN (Online) 2313-4402 
© Global Society of Scientific Research and Researchers  
http://asrjetsjournal.org/  
 
Application of Quality by Design in a Commercialized 
Lyophilized Vaccine 
Alexander da Silva Neves
a*
, Antonio Carlos Augusto da Costa
b





Programa de Pós-Graduação em Engenharia Química, PPG-EQ, Universidade do Estado do Rio de Janeiro, 
Rua São Francisco Xavier, 524 – Maracana, 20550-0900, Rio de Janeiro, Brazil 
a,c
Bio-Manguinhos/Fiocruz, Instituto de Tecnologia em Imunobiológicos, Av. Brasil, 4365 - Manguinhos, 
21040-900, Rio de Janeiro, Brazil 
a







The pharmaceutical industry has being implementing regulatory practices to assure that consumers obtain 
products with quality, safety, and efficacy. The use of Quality by Design (QbD) for products on development 
has increased though the years to avoid issues related to quality parameters and has been suggested by 
Regulatory Agencies to standardize globally the documentation for the registration of new products. Although 
the concepts of QbD gain importance, it is still not a widespread practice to existing systems and products 
already on the market. This work aims to propose a case study with a vaccine using QbD concepts on the 
lyophilization unit operation production step to provide robustness and increase efficiency, leading to a 
lyophilization cycle time reduction. To this end, a reverse way of the use of QbD principles were applied based 
on historical batches database, down scale experiments, and finally in industrial scale to establish new 
boundaries in the lyophilization cycle. Experimental batches samples were analyzed through accelerated and 
real time stability study. At the end, this case became a possibility to establish new ranges to lyophilization 
process predicting risks and assure robustness to this production step with the maintenance of quality and safety 
of vaccine.  
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1. Introduction  
Biological drug production is a complex operation involving many agents, materials, equipment, and 
technologies, transforming the pharmaceutical industry into a highly regulated entity through quality policies 
and regulation authorities. Although the first Quality by Design (QbD) approach was outlined almost thirty 
years ago [1], the increase in the pharmaceutical industry began after the creation of the guidelines of 
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) 
and the Regulatory Agencies from Europe (EMA) and EUA (FDA) starting to emphasize the QbD component 
as part of regulatory filing for new developed drugs. FDA started to shift from the traditional approach, which 
includes a rigorous testing of the final product (Quality by Test), to a risk-based Quality by Design (QbD) 
approach [2 – 3]. QbD is focused on process design; the relationship with a risk-based approach has been 
discussed in ICH Q8 and Q11 [4-5]. The step by step to implement QbD for development of pharmaceutical 
products has been established [5-10] in Figure 1. 
 
Figure 1: QbD General Application Roadmap – Adapted [5-10] 
The most important components of the QbD used in the pharmaceutical industry were [4, 6, 11]: Quality target 
product profile (QTPP): A prospective summary of the quality characteristics of a drug product that will, 
ideally, if achieved ensure the desired quality, taking into account safety and efficacy of the drug product [4], 
Critical quality attributes (CQAs): A physical, chemical, biological, or microbiological property or characteristic 
that should be within an appropriate limit, range, or distribution to ensure the desired product quality [4], 
Critical process parameters (CPP): A process parameter for which the variability has an impact on a CQA and 
therefore should be monitored or controlled to ensure the process produces the desired quality [4], Critical 
material attributes (CMAs): A physical, chemical, biological or microbiological property or characteristic of an 
input material that should be within an appropriate limit, range, or distribution to ensure the desired quality of 
output material [11]. However, guidelines from ICH do not mention the use of QbD for products already on the 
market. In this paper, the QbD principles and its components will be applied for a vaccine lyophilization 
production step that has been produced in Brazil since 1937, first by the Oswaldo Cruz Institute and later in the 
1980s by the Institute of Immunobiological Technology - Bio-Manguinhos [12]. After more than thirty years in 
the market, the process for this vaccine respond to epidemic outbreaks but was not revised by the QbD concepts. 
The lyophilization process for this vaccine was established before the QbD principles. At that time, the variation 
of CPP influencing the CQA was based on the lyophilization cycle setpoints (temperature, pressure, and time) 
and the capability of the freeze dryer in automatic mode to control those setpoints. This capability and sources 
of variability that could have a negative influence in product quality was addressed by risk analysis by a 
multidisciplinary team of specialists. Freeze-drying is a complex and multistage process that needs to be 
adjusted for each product, making its primary characteristic – drying in a frozen state – a desirable feature. 
Lyophilization process represents a viable alternative formulation strategy to improve biologic products stability 
and long-term storage as well as their ease of shipping and handling. A traditional lyophilization cycle consists 




of the freezing step, the primary step and secondary drying step [13]. Although lyophilization leads to the 
stabilization of biological products, the high investment costs associated with the acquisition of large-scale 
freeze-drying equipment, high-energy demand, and high process operation times, make freeze-drying a 
challenge for the pharmaceutical industry [14 - 17]. For commercial purpose, process costs are as important as 
product quality, which leads to a desire to optimize the process, particularly the heat and mass transfer and the 
formulation of the product to be lyophilized [18]. The primary focus of this study was to use Qbd principles on 
the lyophilization unit operation to allow the vaccine production with wide ranges of lyophilization CPP to 
achieve the same CQA results in order to maintain the quality of the final product. To measure and guide the 
methodology regarding the case study for the vaccine, a SWOT analysis for the lyophilization unit operation 
using QbD principles were developed. 
 
Figure 2: QbD SWOT analysis for the lyophilization unit operation. Strengths, weaknesses, opportunities, and 
threats available on the vaccine producer. 
With the SWOT analysis applied the QbD principles for the lyophilization unit operation, a trade-off of 
weakness and opportunities had the major bullets. Clearly, there are a bunch of opportunities that QbD can bring 
to the unit operation, however, a lot of work, investment, and time consuming are expected as weaknesses for all 
process. It could be an opportunity to apply QbD principles focusing on lyophilization unit operation for 
products in the market updating documents and understanding better the freeze dryer cycle CPP and the impacts 
in CQAs of the product. Once, this knowledge is absorbed, increase productivity can be verified with new 
lyophilization cycle times. The authors in [19] developed and optimized a lyophilized formulation of simvastatin 
thought the successful application of QbD approach relationshiping the influence of two developed formulation 
and process parameters on the CQAs of lyophilization of simvastatin determined using DoE. The influence of 
several risk factors (three formulation factors and two process parameters over the critical quality attributes of 
lyophilized long circulating liposomes with simvastatin) was investigated within the current study using the 
design of experiments tool of QbD. Moreover, the design space was determined, in which the established quality 
requirements of the product are met, provided that the risk factors vary within the established limits. Other 
authors in [20], described a rational procedure, based on mathematical modeling, for properly choosing the 
freezing conditions according to the QbD approach to build the design space to describe the impact of freezing 
conditions on product ice crystal size and drying performances demonstrating thought the results the power of 




QbD. A deep understanding of the freezing phenomena was required, and, according to the QbD approach, this 
knowledge was used to build the design space allowing control of the freezing process and fast selection of 
appropriate operating conditions. In this paper the goal is to review the process to establish new ranges for the 
lyophilization cycle CPP using QbD concepts proceeding with a review of commercial batches database, 
propose hypotheses, and with pilot and industrial scale freeze dryer proceed with experiments, based on 
previous knowledge of critical temperature and other product specifications reached by Differential Scanning 
Calorimetry, Freeze dryer Microscope and electric resistance. According to Brazilian National Regulatory 
Agency (ANVISA) regulations, changes in the formulation of the product are classified as level 2 or 3 for 
product registration and can lead to clinical trials to confirm that the modifications will not affect the quality, 
efficiency, and safety of the vaccine [21]. To avoid investment in clinical trials, in this work the formulation and 
fill-and-finish production process steps were not modified. The study focused on the freeze-drying step of a 
vaccine and a review of batches database from 2008 up to 2014 to apply QbD principles and suggest cycle 
experiments on the lyophilization unit operation to establish new ranges of CPP. After formulation and proper 
conditioning in the lyophilizer, a programmed cycle initiates the freeze-drying of the vaccine, which ultimately 
increases its shelf life. The cycle time depends on the specific product being lyophilized and usually requires 
more than three days to obtain a product that meets quality control specifications [22 - 26]. Although Brazil is 
the biggest producer of the studied lyophilized product worldwide, there is still a risk supply discontinuity to 
meet the demand in the country for the National Immunization Program (PNI) and Africa if the epidemiological 
scenario becomes worse. In terms of process management, lyophilization process step is a bottleneck to increase 
the vaccine production during outbreaks. To reach robustness in the freeze-drying cycle in industrial scale, the 
following aspects were conducted: (a) The application of specific QbD principles applied on the vaccine already 
on the market; (b) Based on commercial batches database the suitability of the present freeze-drying cycle for 
the vaccine and changes in CPP to determine the new ranges necessary to make production more flexible and 
minor risks of deviations; (c) The proposal of new lyophilization cycle and conduction of experimental batches 
on a pilot and industrial scale, based on the same formulation and fill and finish procedures; (d) The sampling of 
the experimental batches drug product on an industrial scale to analyze residual moisture content, aspect, pH, 
potency and long-term thermostability; and (e) The similarities between the results against commercial batches, 
thus confirming the benefits of QbD approach.  
2. Material and methods 
2.1. Unit operation observations, deviations and proposed CPP values 
To provide wide ranges on CPP in the lyophilization unit operation the first step of the methodology was a 
review of lyophilization commercial batches cycles and deviations in the database of quality system of the 
product regarding the lyophilization step. The standard procedures for commercial batches are loading the freeze 
dryer manually allowing the product measure with resistance temperature detectors (RTDs) inside the product 
vials monitoring the product temperature along the lyophilization process and recording in the freeze dryer 
database. The profile of the product in commercial batches in freezing, primary and secondary drying step are 
presented in Figure 3. 





Figure 3: Registration of three product temperatures monitored along a commercial production. 
The data from Figure 3 presents no variability between product temperatures (Tprod1, Tprod2, Tprod3). The 
industrial freeze dryer shelves temperature (Tin) are controlled automatically in temperature ranges of ±1.5°C 
from the shelf setpoint. Temperatures out of this range represents a deviation on quality system of the company. 
The product freeze dryer cycle loading temperature is positive and product temperatures during freezing step are 
below -40ºC achieved after 2:30h. The posterior time during freezing step is important to have temperature 
homogeneity of the vials, although no product temperatures significantly changes are observed. During primary 
step, the product is kept for 8h with no product temperatures significant temperature changes observed and in 
secondary step when the product reaches a constant temperature over time. With those observations the regions 
of the lyophilization cycle that could enhanced were mapped and will be challenged with experiments. The 
magnitude of the deviation regarding the CPP (temperature, time, and pressure) in each cycle step were 
correlated to the CQA results from Quality Control in each experiment. 
2.2. Proposal modifications in freeze dryer cycle CPP  
Based on the correlation results and the product temperature database from commercial lyophilization cycles 
available, a new lyophilization cycles experiments were proposed to predict the impact on CQAs with the 
modification on CPPs setpoints of the lyophilization unit operation of the vaccine. The decision was supported 
by an impact analysis (Table I) approach conduct as a second step. The strategy was first conducted using 
downscaled batches in pilot freeze dryer and after adjusted the parameters to the industrial equipment. The 
suitability of the present freeze-drying cycle to changes in CPPs was aligned for new ranges necessary for 
flexibility of production without deviations. 
Table 1: Resume of impact analysis for proposed CPP modifications on lyophilization Cycle 
Lyophilization Cycle 
Step 




Aspect, Potency, Residual Moisture, pH 
High* 
Freezing Temperature and Time High* 
Primary Drying Time High* 
Secondary Drying Temperature High* 




*Product Impacts: High – Modification has high probability to results out of range of CQA  
2.3. Experimental batches 
Six experimental batches were designed as the third step. Three experiments were produced using an automatic 
pilot freeze dryer IMA Lyoflex with capacity of 2,000 vials full loaded and three experimental batches using 
automatic industrial freeze dryers IMA Lyomax with capacity of 36,000 vials full loaded. Both freeze dryers are 
equipped with a capacitance manometer (Barocell; mks, USA) and has a setpoint temperature deviation of 
±1.5°C and pressure setpoint deviation of ±0,50µHg. The product temperature was measured by RTD probes 
and endpoint of primary drying by the manometric temperature measurement. All the experiments were 
performed following the same vaccine primary raw materials (20mL amber Schott vials and 20mm West rubber 
stoppers), formulation ratio, and quantities of API, sucrose, glutamate, sorbitol, hydrolyzed bovine gelatin, 
erythromycin, kanamycin, and water for injection, fill-and-finish steps in Bosch filling line Model, 
lyophilization in IMA freeze dryers, production procedures, documentation traceability and validations 
established for commercial batches. Lyophilization cycle evaluation proposed new CPP ranges for the shelf 
temperature and time cycle step. In this study, pressure during lyophilization was not modified from the original 
freeze dryer cycle. 
Experiment 1 – Downscaled Batches  
During the production of three commercial batches, 720 vials of each commercial batch were sent to IMA pilot 
freeze-dryer and the batches were named as A1, A2 and A3. The Experimental 1 batches were produced with 
different CPP set points (Table 2), reducing or increasing shelves temperature and time compared to the current 
cycle for industrial batches. 
















Cycle Total Time 
Reduction 
A1 15°C reduction 1h 4°C 14h  3°C 17h 
A2 Sub-zero 1h 4°C 14h  3°C 17h 
A3 Sub-zero 2h 4°C 16h 3°C 20h 
The objective of those experiments was to preview if the product could be loaded at subzero temperatures, if the 
observation from lyophilization cycles database could be applied to lower the shelf temperature and time of the 
freezing step, if the dead time observed in the three phases of the lyophilization cycle could be reduced and, at 
least, if the product could handle high temperatures in the secondary step. 
Experiment 2 – Industrial scale freeze dryer cycle  




 To perform experiments in industrial freeze dryers, the lyophilization cycle in experimental 1 was scaled-up 
and three identical experiments (B1, B2, B3) were produced (Table 3). 













Cycle Total Time 
Reduction 




4°C reduction 12h reduction 3°C increased 15h B2 
B3 
2.4. Analytical determinations 
To confirm the results, each batch was analyzed regarding CQA aspect, residual moisture, potency, and pH 
(Table 4). 
Table 4: CQA analyzed for each experiment 
CQA Analysis Method Specification Reference 
Aspect 
Automatic and visual inspection / 
Reconstitution by adding sterile 
water 
Compact cake / opalescent 
suspension slightly pinkish-yellow 
Producer  
Residual moisture 
Karl-Fischer coulometric titration 
Maximum 3%  WHO [27] 
Potency  
Methodology for 50% Cell Culture 
Infective Dose  
Equal or higher than 3.73 log 10 
PFU/HD  
WHO [27] 
pH Methrom 780 pHmeter from 6.5 to 7.5 at 25°C. Producer  
Following to experiment 1, six months accelerated stability studies and twenty-four months real time stability 
study were conducted to confirm the suitability of the lyophilization cycle before experiment 2 industrial scale. 
For the experiment 2, six months accelerated stability studies and 36 months real time stability study were 
conducted in 2-8°C and -20°C storage conditions according to ANVISA and WHO regulations [21, 27]. 
3. Results and discussion 
The proposed industrial freeze dryer experiments loading the product on sub-zero shelf temperature and with 
reduced freezing step temperature in 4°C with less than two hours leads to changes in the product temperature 
profile during the freezing step (Figure 4). 





Figure 4: Comparison freezing step product profile commercial (legacy) vs experiment. 
Lines 1, 2, and 3 represent the product profile monitored during commercial production (legacy) in freezing 
lyophilization cycle step. Lines 4, 5 and, 6 represent the new product profile in freezing step during Experiment 
2 in the industrial freeze dryer. As expected, from figure 4, the product from experiment 2 achieves negative 
temperatures faster and lower than commercial batches avoiding the time related to decrease product 
temperature necessary on commercial batches. Although, it could lead to different ice morphology and impacts 
the degree of super-cooling and, for last, the primary step time [28]. From the primary drying step perspective, 
the shelf temperature and chamber pressure setpoints were the same used in commercial batches. It was 
observed that the product profile in experiments in industrial freeze dryer changes increasing product 
temperatures along this lyophilization step (Figure 5). 
 
Figure 5: Comparison primary drying product profile commercial (legacy) vs experiment. 
Lines 1, 2, and 3 represent the product profile during commercial production (legacy) in primary drying 
lyophilization cycle step. Lines 4, 5, and 6 represent the new product profile monitored in primary drying step 
during Experiment 2 in the industrial freeze dryer. From figure 5, the Experiment 2 product achieves superior 
temperatures than the commercial batches, but with a shorter primary drying time step of 12h. This could be 
also be related to the degree of super-cooling and resistance of mass transfer influencing primary drying times 




[28]. No different profile was observed in the secondary drying step with the proposal of increase the shelf 
temperature in the experiments maintaining the same chamber pressure setpoint used in commercial batches 
(Figure 6). 
 
Figure 6: Comparison secondary drying product profile commercial (legacy) vs experiment. 
Lines 1, 2, and 3 represent the product profile during commercial production (legacy) in secondary drying 
lyophilization cycle step. Lines 4, 5, and 6 represent the new product profile monitored in secondary drying step 
during Experiment 2 in the industrial freeze dryer. From figure 6, the increase in shelf temperature setpoint in 
3°C with the same pressure setpoint and step time used in commercial batches during secondary lyophilization 
step do not represent a new product profile for the experimental batches.   From legacy, previous stability 
studies with the vaccine produced in commercial scale were evaluated in three different storage conditions 
during long term and accelerated stability studies for thirty-six months (Table 5). 
Since the CQA can change along the shelf time, stability studies in different storage temperatures were 
conducted in Experiment 2 batches to compare with the vaccine commercial batches studies to evaluate the 
freeze dryer cycle modifications proposed with the same accelerated stability conditions during six months at 
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From Table 4, average CQA residual moisture, potency and pH for all Experiment 2 batches were according 
with the specifications and presents similar results compare with Commercial Batches confirming that CPP 
changes in the lyophilization cycle does not change the CQA of the product. In all the Experiment 2 batches, the 
aspect of the cake appeared to be compact and without collapsed cakes (Figure 7) after evaluation by visual 
inspection and reconstitution analysis performed. 
 
Figure 7: Product aspect of commercial and experimental 2. A) Commercial product cake B) and C) 
Experimental 2 product cake. 
No excipients were introduced into the system or the formulation step to improve the appearance of the cake or 
to enhance any other property of the product in both experiments. After 100% visual inspection, a yield of 94% 
of the vials were approved of each experimental 2 batches and no impact on CQA aspect of the cake or after 
reconstitution was observed during the stability studies with different storage conditions.  An improvement on 
the freeze-drying process for a tuberculosis vaccine by obviating the need for maintenance of the product at low 
temperatures was reached [26]. This change was for a freeze-drying process that used an abrupt change of 
storage conditions of the product at low temperatures. The authors were able to maintain the activity and 
stability of the vaccine before and after the introduction of the changes in the freeze-drying cycle. In a review 
about the freezing stage of lyophilization [18], the consequences of freezing step were studied on the overall 
performance of the freeze-drying process, and the quality of biopharmaceutical products and emphasized that a 
deep understanding of the freezing stage and the ability to control freezing more efficiently, are key factors in 
improving the quality and stability of pharmaceutical products. The authors in [29] studied the thermal stability 
of a mannitol formulation by introducing sodium chloride to the lyophile. The authors concluded that the 
presence of sodium chloride contributed to higher stability of the formulated product, thus counteracting 
problems associated with change in the aspect of the lyophile, particularly crystallization. A procedure of 
emulsification with lyophilization, where adjuvants were prepared as albumin carriers and produced a dry 
product whose stability was confirmed by storage at room temperature. The product formed was able to induce 
systemic immune responses, efficiently acting as potent vaccines without the need for storage at cold 
temperatures [23].  Aggregation was observed due to the presence of colloidal aluminum hydroxide in 
formulations processed after rapid cooling. Rats immunized with the reconstituted vaccine produced specific 
antibodies and toxin neutralizers, irrespective of the duration of the high temperature storage or the level of 
aggregation of the adjuvant during lyophilization. In those rat studies, lyophilized formulations of the vaccine 
protected against lethal doses of ricin, even when formulations were stored at 40°C for 4 weeks. On the other 




hand, the liquid formulation of the same vaccine, stored under similar conditions, was not effective against ricin 
[30]. Many authors, to achieve better results in the lyophilized product stability proceed with changes in the 
formulation of the products. On other hand, in this study no formulation changes were applied and the average 
CQA results for residual moisture, potency, and pH during accelerated and long-term stability studies in 
different storage conditions for Experimental 2 batches showed quite satisfactory and similar to commercial 
batches in industrial scale. Figures 8 show the profile stability study in different storage conditions for CQA 
residual moisture and Figure 9 for potency from Experimental 2 batches and from commercial batches of 
vaccine. 
 
Figure 8: Profile of long-term residual moisture stability study in different storage conditions. a) b) long-term 
stability for residual moisture at 2-8ºC for Experimental 2 and commercial batches c) d) long-term stability for 
residual moisture at -20ºC for Experimental 2 and commercial batches 
The profile of long-term stability result from Experimental 2 batches and from commercial batches of vaccine 
are very similar with crescent growing of residual moisture below the maximum limit of 3% and below 2% 
along the thirty-six months of stability study under 2-8°C storage. From the CQA potency perspective, the 
profile of long-term stability result from experimental 2 batches and from commercial batches of the vaccine are 
very similar with variations of potency above the minimum limit of 3.0 Log 10 LD50/dose and with values 
above 4,14 Log 10 LD50/dose demonstrating comparability and no significant  changes in the thermostability 
profile of the vaccine with proposed CPP changes for the lyophilization unit operation cycle. In relation to the 
loss associated with accelerated thermostability of the experimental batches as a function of the freeze-drying 
time, all the results were satisfactory (all losses were less than or equal to 1 log PFU/HD).  Regarding pH, all the 
experimental batches results are within the requirements and maximum value is 6.9 when vaccine is storage at -
20ºC. Comparing with commercial batches there were no significant changes. 





Figure 9:  Profile of long potency stability study in different storage conditions. a) b) long-term stability for 
potency at 2-8ºC for Experimental 2 and commercial batches c) d) long-term stability for potency at -20ºC for 
Experimental 2 and commercial batches. 
This suggests that the freezing and postfreezing CPP changes in the freeze-drying cycle with 15h less were 
effective for the viral vaccine test in this work and will be beneficial for this product and the CQA potency were 
not impacted. Performing the reduction of cycle time in the sequence of vaccine manufacturing showed benefits 
in cost investment of new equipments to increase production, vaccine availability, lead-time to market and 
others once the lyophilization is usually a bottleneck in production activities. Vaccine producers face challenges 
associated with maintaining consistent supply due to complexity and high fixed costs of vaccine manufacturing, 
regulations, and commercial requirements to supply these vaccines at affordable prices [31]. If installed, 
capacity of vaccine manufacturing is too large, the fixed costs increase per-unit dose cost and, on the other hand, 
capacity that is lower than the market can lead to lack of flexibility of supply as market conditions change. 
Decreasing the freeze-drying cycle time may lead to higher availability of the lyophilizer, consequently 
increasing the number of batches that can be produced within a specific period [18, 30 - 34]. With the actual 
commercial freeze dryer and the Experiment 2 results a range for the CPP temperature and time for the 
lyophilization steps could be stablished. 
Table 7: CPP Ranges for vaccine Freezing Dryer Cycle 
Freeze Dryer CPP CPP New Range 
Temperature (Loading Step) Positive to Sub-zero 
Time (Freezing Step) 5h to 2h 
Temperature (Freezing Step) From Commercial setpoint cycle to less 4°C 
Time (Primary Drying Step) From 24h to 12h 
Temperature (Secondary Drying Step) From Commercial setpoint cycle to more 3°C 




From the results, Table 7 describe ranges of CPP possible to be used for the vaccine lyophilization cycle in this 
study.  Loading step temperature could be positive or negative, but the freezing step time will depend on that for 
a homogenous freeze state of the vials in the freeze dryer. From the standpoint of temperature in the freezing 
step, variations below 4°C from the setpoint can be implemented. If the freezing step is well succeeded, the 
primary drying step can vary from 12h to 24h. Lastly, variations above 3°C in secondary dry step can be 
implemented. Since these boundaries represents values which the set point can vary it these variations will not 
represent risks to product quality.   
4. Conclusions 
This work describes how QbD principles and contents can be applied on a product that has been commercialized 
for a long time and propose, based on scientific knowledge, improvements on the lyophilization production step 
for the vaccine. The use of QbD principles were supported by commercial batches results database and the 
suitability of lyophilization cycle change. With no modifications in the formulation of the product, a criticality 
analysis was performed in the freeze dryer cycle followed to an impact analysis to establish experiments in 
small scale providing scientific evidences for proposed changes on CPP ranges temperature and time on the 
industrial lyophilization unit operation. The experiments results in a small scale freeze dryer were according 
with the product CQA specification and provided more data to propose a lyophilization cycle scale up for the 
commercial scale industrial freeze-dryers. The industrial scale batches with the suggested CPP boundaries 
analyzed for thirty-six months real time stability at 2-8ºC and at -20ºC demonstrated profile and results in 
accordance with WHO minimum requirements and similar results with current freeze dryer cycle. Wider ranges 
for cycle CPPs were established for the lyophilization cycle so that the producer can guarantee, under the new 
limits, no interference on product quality if variations occurs during the lyophilization process. Thus, by 
decreasing 15h the lyophilization cycle time the number of produced batches per year can be increased with the 
same number of industrial freeze dryers. Those improvements are aligned with the strategies of the Brazilian 
National Immunization Program and WHO to contribute to the global stockpile of vaccines for emergency 
outbreaks. The concept of QbD and the methodology suggested in this paper can be applied to others biological 
lyophilized products on the market with scientific data acquisition, less product deviations and productivity 
increase. 
5. Recommendations 
Even though initial investments may be required for analysis of product specifications and process critical 
parameters to apply QbD concepts in small scale, the understanding of process multivariate parameters, the 
possibility of continuous improvement, risk mitigation of batches failures and alignment with Regulatory 
Authorities, who charge manufacturers for knowledge and control of his own process based on scientific 
matters, are some of the advantages that goes beyond of initial financial return. The use of batches database, risk 
analysis and Corrective Action Preventive Action could be the first step to planning future applications of the 
QbD principles aiming the redesign of existing systems of pharmaceuticals products already on the market and 
could avoid, initially, Design of Experiments due to the wide range of information already available in the 
manufacturer site. For future works, advances in others lyophilization CPP could be related to CQA of the 
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